This single center phase I trial investigated 12 patients with CD30+ lymphoma (AITL: n = 5; relapsed HL: n = 7; median of two previous treatment lines) undergoing ASCT. The gene discussed is TNFRSF8; the disease is angioimmunoblastic T-cell lymphoma.